Профиль Curasight A-S Bearer and-or registered Shs
Подробнее
Curasight A/S is a clinical development company, which engages in the field of exploiting a novel Positron Emissions Tomography (PET) imaging platform targeting the urokinase-type plasminogen activator receptor (uPAR). It provides diagnosis and risk stratification in multiple cancer types, most notably for risk stratification in prostate cancer. The company was founded by Morten Persson, Andreas Kjaer, Carsten Haagen Nielsen, and Jacob Madsen in 2013 and is headquartered in Copenhagen, Denmark.